ADVERTISEMENT

Type 2 diabetes: gastrointestinal side effects vary across GLP-1 agonists

Miriam Tucker   |   Clinical Summary   |   04 January 2023
ADVERTISEMENT

Semaglutide had the highest rates of GI symptoms, while liraglutide was associated with more upper abdominal pain.

Takeaway

  • In US adverse event (AE) reporting, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were significantly associated with gastrointestinal (GI) AEs.
  • Semaglutide had the greatest risk for nausea, diarrhoea, vomiting, constipation, and pancreatitis, while liraglutide was...

          

Topic Challenges

left
right